A Study of Q-1802 in Patients With Advanced Solid Tumors

Summary

Q-1802 is a bispecific antibody targeting both the tumor-specific antigen Claudin 18.2 and the immune checkpoint PD-L1. This is a multi-center, single-arm, open-label design to evaluate the safety and tolerance of Q-1802 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy. The study consisted of two compartments: the dose-exploration stage and the dose-extension stage.

Timeline

Start

2021-05-21

Primary completion

2024-04

Completion

2024-07

Drugs

Indications